Showing 221-230 of 325 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Optimizing islet cell graft performance with targeted alpha and beta cell composition and distribution | Mayo Clinic | Quinn Peterson | Cures | 01-April-2025 to 31-March-2027 | $699,138.64 |
| A Nanosensor Embedded Device for Rapid Insulin Measurement | Massachusetts Institute of Technology | Michael Strano | Improving Lives | 01-April-2024 to 31-March-2027 | $600,000.00 |
| The T1D Parent Check-In: A Preventative Intervention | Massachusetts General Hospital | Ellen O'Donnell | Improving Lives | 01-July-2023 to 30-June-2026 | $390,792.17 |
| Understanding common tissue tolerance mechanisms in autoimmunity | Massachusetts General Hospital | Gary Reynolds | Cures | 01-September-2025 to 31-August-2026 | $150,000.00 |
| Development of a safe and effective islet-targeted nanoplasmid based CXCL12 gene delivery system using cationic nanobubble-mediated sonotransfection to restore and immune protect the residual beta cell mass in T1D | Massachusetts General Hospital | Mark Poznansky | Cures | 01-April-2023 to 31-March-2026 | $777,168.00 |
| Demand for Combined CGM-Pump Devices in Type 1 Diabetes | Magnolia Innovation, LLC | Kenneth Howie | Improving Lives | 01-August-2025 to 15-February-2026 | $291,000.00 |
| T1D Adjunct Therapy Product & Patient Profiling Study | Magnolia Innovation, LLC | Kenneth Howie | Improving Lives | 01-December-2024 to 31-December-2025 | $434,000.00 |
| Transcriptional memory in human islet organogenesis | Lundquist Institute for Biomedical Medical Innovation at Harbor‐UCLA Medical Center (The Lundquist Institute) | Eiji Yoshihara | Cures | 01-April-2022 to 31-March-2027 | $749,995.50 |
| Innovation Partnership | LabCentral | Luke Wallrich | Cures | 07-July-2025 to 31-May-2026 | $200,000.00 |
| Effectiveness and safety of sotagliflozin in slowing kidney function decline in persons with type 1 diabetes and moderate to severe diabetic kidney disease: The SUGARNSALT Trial | Joslin Diabetes Center Inc. | Alessandro Doria | Improving Lives | 01-January-2024 to 31-December-2028 | $8,913,450.00 |